{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T22:06:12Z","timestamp":1772143572389,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan","doi-asserted-by":"crossref","award":["18H02923"],"award-info":[{"award-number":["18H02923"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["17ek0109215h0001"],"award-info":[{"award-number":["17ek0109215h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Achondroplasia is caused by gain-of-function mutations in <jats:italic>FGFR3<\/jats:italic> gene and leads to short-limb dwarfism. A stabilized analogue of C-type natriuretic peptide (CNP) is known to elongate bone by interacting with FGFR3 signals and thus is a promising drug candidate. However, it needs daily administration by percutaneous injection. FGFR inhibitor compounds are other drug candidates for achondroplasia because they directly fix the mutant protein malfunction. Although FGFR inhibitors elongate the bone of model mice, their adverse effects are not well studied. In this study, we found that a new FGFR inhibitor, ASP5878, which was originally developed as an anti-cancer drug, elongated the bone of achondroplasia model male mice at the dose of 300\u00a0\u03bcg\/kg, which confers an AUC of 275\u00a0ng\u00b7h\/ml in juvenile mice. Although ASP5878 was less effective in bone elongation than a CNP analogue, it is advantageous in that ASP5878 can be administered orally. The AUC at which minimal adverse effects were observed (very slight atrophy of the corneal epithelium) was 459\u00a0ng\u00b7h\/ml in juvenile rats. The positive discrepancy between AUCs that brought efficacy and minimal adverse effect suggests the applicability of ASP5878 to achondroplasia in the clinical setting. We also analyzed effects of ASP5878 in a patient-specific induced pluripotent stem cell (iPSC) model for achondroplasia and found the effects on patient chondrocyte equivalents. Nevertheless, cautious consideration is needed when referring to safety data obtained from its application to adult patients with cancer in clinical tests.<\/jats:p>","DOI":"10.1038\/s41598-020-77345-y","type":"journal-article","created":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T11:05:07Z","timestamp":1606820707000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Evaluation of FGFR inhibitor ASP5878 as a drug candidate for achondroplasia"],"prefix":"10.1038","volume":"10","author":[{"given":"Tomonori","family":"Ozaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Kawamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Iimori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Takeshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiko","family":"Yamagishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masazumi","family":"Kamohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaori","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Tanahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Tsumaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,1]]},"reference":[{"key":"77345_CR1","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/dvdy.24479","volume":"246","author":"DM Ornitz","year":"2017","unstructured":"Ornitz, D. M. & Legeai-Mallet, L. Achondroplasia: Development, pathogenesis, and therapy. Dev. Dyn. 246, 291\u2013309. https:\/\/doi.org\/10.1002\/dvdy.24479 (2017).","journal-title":"Dev. Dyn."},{"key":"77345_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S0140-6736(07)61090-3","volume":"370","author":"WA Horton","year":"2007","unstructured":"Horton, W. A., Hall, J. G. & Hecht, J. T. Achondroplasia. Lancet 370, 162\u2013172. https:\/\/doi.org\/10.1016\/S0140-6736(07)61090-3 (2007).","journal-title":"Lancet"},{"key":"77345_CR3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/371252a0","volume":"371","author":"F Rousseau","year":"1994","unstructured":"Rousseau, F. et al. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 371, 252\u2013254 (1994).","journal-title":"Nature"},{"key":"77345_CR4","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/0092-8674(94)90302-6","volume":"78","author":"R Shiang","year":"1994","unstructured":"Shiang, R. et al. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 78, 335\u2013342 (1994).","journal-title":"Cell"},{"key":"77345_CR5","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S0092-8674(00)81069-7","volume":"84","author":"C Deng","year":"1996","unstructured":"Deng, C., Wynshaw-Boris, A., Zhou, F., Kuo, A. & Leder, P. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84, 911\u2013921 (1996).","journal-title":"Cell"},{"key":"77345_CR6","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/ng0395-321","volume":"9","author":"PL Tavormina","year":"1995","unstructured":"Tavormina, P. L. et al. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat. Genet. 9, 321\u2013328. https:\/\/doi.org\/10.1038\/ng0395-321 (1995).","journal-title":"Nat. Genet."},{"key":"77345_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.61366","author":"GR Mortier","year":"2019","unstructured":"Mortier, G. R. et al. Nosology and classification of genetic skeletal disorders\u202f: 2019 revision. Am. J. Med. Genet. A https:\/\/doi.org\/10.1002\/ajmg.a.61366 (2019).","journal-title":"Am. J. Med. Genet. A"},{"key":"77345_CR8","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/MOP.0b013e32833b7a69","volume":"22","author":"MB Laederich","year":"2010","unstructured":"Laederich, M. B. & Horton, W. A. Achondroplasia: Pathogenesis and implications for future treatment. Curr. Opin. Pediatr. 22, 516\u2013523. https:\/\/doi.org\/10.1097\/MOP.0b013e32833b7a69 (2010).","journal-title":"Curr. Opin. Pediatr."},{"key":"77345_CR9","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1210\/en.2008-1676","volume":"150","author":"A Yasoda","year":"2009","unstructured":"Yasoda, A. et al. Systemic administration of C-type natriuretic peptide as a novel therapeutic strategy for skeletal dysplasias. Endocrinology 150, 3138\u20133144. https:\/\/doi.org\/10.1210\/en.2008-1676 (2009).","journal-title":"Endocrinology"},{"key":"77345_CR10","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.ajhg.2012.10.014","volume":"91","author":"F Lorget","year":"2012","unstructured":"Lorget, F. et al. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. Am. J. Hum. Genet. 91, 1108\u20131114. https:\/\/doi.org\/10.1016\/j.ajhg.2012.10.014 (2012).","journal-title":"Am. J. Hum. Genet."},{"key":"77345_CR11","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1124\/jpet.114.218560","volume":"353","author":"DJ Wendt","year":"2015","unstructured":"Wendt, D. J. et al. Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism. J. Pharmacol. Exp. Ther. 353, 132\u2013149. https:\/\/doi.org\/10.1124\/jpet.114.218560 (2015).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"77345_CR12","doi-asserted-by":"publisher","first-page":"3941","DOI":"10.1093\/hmg\/dds181","volume":"21","author":"Y Xie","year":"2012","unstructured":"Xie, Y. et al. Intermittent PTH (1\u201334) injection rescues the retarded skeletal development and postnatal lethality of mice mimicking human achondroplasia and thanatophoric dysplasia. Hum. Mol. Genet. 21, 3941\u20133955. https:\/\/doi.org\/10.1093\/hmg\/dds181 (2012).","journal-title":"Hum. Mol. Genet."},{"key":"77345_CR13","doi-asserted-by":"publisher","first-page":"5443","DOI":"10.1093\/hmg\/dds390","volume":"21","author":"M Jin","year":"2012","unstructured":"Jin, M. et al. A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia. Hum. Mol. Genet. 21, 5443\u20135455. https:\/\/doi.org\/10.1093\/hmg\/dds390 (2012).","journal-title":"Hum. Mol. Genet."},{"key":"77345_CR14","doi-asserted-by":"publisher","first-page":"203ra124","DOI":"10.1126\/scitranslmed.3006247","volume":"5","author":"S Garcia","year":"2013","unstructured":"Garcia, S. et al. Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice. Sci. Transl. Med. 5, 203ra124. https:\/\/doi.org\/10.1126\/scitranslmed.3006247 (2013).","journal-title":"Sci. Transl. Med."},{"key":"77345_CR15","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1210\/en.2014-1914","volume":"156","author":"M Matsushita","year":"2015","unstructured":"Matsushita, M. et al. Meclozine promotes longitudinal skeletal growth in transgenic mice with achondroplasia carrying a gain-of-function mutation in the FGFR3 gene. Endocrinology 156, 548\u2013554. https:\/\/doi.org\/10.1210\/en.2014-1914 (2015).","journal-title":"Endocrinology"},{"key":"77345_CR16","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nature13775","volume":"513","author":"A Yamashita","year":"2014","unstructured":"Yamashita, A. et al. Statin treatment rescues FGFR3 skeletal dysplasia phenotypes. Nature 513, 507\u2013511. https:\/\/doi.org\/10.1038\/nature13775 (2014).","journal-title":"Nature"},{"key":"77345_CR17","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1172\/jci83926","volume":"126","author":"D Komla-Ebri","year":"2016","unstructured":"Komla-Ebri, D. et al. Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model. J. Clin. Invest. 126, 1871\u20131884. https:\/\/doi.org\/10.1172\/jci83926 (2016).","journal-title":"J. Clin. Invest."},{"key":"77345_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1056\/NEJMoa1813446","volume":"381","author":"R Savarirayan","year":"2019","unstructured":"Savarirayan, R. et al. C-type natriuretic peptide analogue therapy in children with achondroplasia. N. Engl. J. Med. 381, 25\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1813446 (2019).","journal-title":"N. Engl. J. Med."},{"key":"77345_CR19","doi-asserted-by":"publisher","first-page":"7066","DOI":"10.1021\/jm2006222","volume":"54","author":"V Guagnano","year":"2011","unstructured":"Guagnano, V. et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamin o]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J. Med. Chem. 54, 7066\u20137083. https:\/\/doi.org\/10.1021\/jm2006222 (2011).","journal-title":"J. Med. Chem."},{"key":"77345_CR20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/1535-7163.mct-16-0188","volume":"16","author":"T Futami","year":"2017","unstructured":"Futami, T. et al. ASP5878, a novel inhibitor of FGFR1, 2, 3, and 4, inhibits the growth of FGF19-expressing hepatocellular carcinoma. Mol. Cancer Ther. 16, 68\u201375. https:\/\/doi.org\/10.1158\/1535-7163.mct-16-0188 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"77345_CR21","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/cas.13124","volume":"108","author":"A Kikuchi","year":"2017","unstructured":"Kikuchi, A. et al. ASP5878, a selective FGFR inhibitor, to treat FGFR3-dependent urothelial cancer with or without chemoresistance. Cancer Sci. 108, 236\u2013242. https:\/\/doi.org\/10.1111\/cas.13124 (2017).","journal-title":"Cancer Sci."},{"key":"77345_CR22","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s10637-019-00780-w","volume":"38","author":"N Yamamoto","year":"2020","unstructured":"Yamamoto, N. et al. A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1\u20134, as a single dose and multiple doses in patients with solid malignancies. Invest. New Drugs 38, 445\u2013456. https:\/\/doi.org\/10.1007\/s10637-019-00780-w (2020).","journal-title":"Invest. New Drugs"},{"key":"77345_CR23","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.lfs.2015.10.025","volume":"152","author":"S Dutta","year":"2016","unstructured":"Dutta, S. & Sengupta, P. Men and mice: Relating their ages. Life Sci. 152, 244\u2013248. https:\/\/doi.org\/10.1016\/j.lfs.2015.10.025 (2016).","journal-title":"Life Sci."},{"key":"77345_CR24","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1242\/dev.125.24.4977","volume":"125","author":"MC Naski","year":"1998","unstructured":"Naski, M. C., Colvin, J. S., Coffin, J. D. & Ornitz, D. M. Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. Development 125, 4977\u20134988 (1998).","journal-title":"Development"},{"key":"77345_CR25","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.stemcr.2015.01.016","volume":"4","author":"A Yamashita","year":"2015","unstructured":"Yamashita, A. et al. Generation of scaffoldless hyaline cartilaginous tissue from human iPSCs. Stem Cell Rep. 4, 404\u2013418. https:\/\/doi.org\/10.1016\/j.stemcr.2015.01.016 (2015).","journal-title":"Stem Cell Rep."},{"key":"77345_CR26","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/j.joca.2018.07.015","volume":"26","author":"T Kimura","year":"2018","unstructured":"Kimura, T. et al. Proposal of patient-specific growth plate cartilage xenograft model for FGFR3 chondrodysplasia. Osteoarthr. Cartil. 26, 1551\u20131561. https:\/\/doi.org\/10.1016\/j.joca.2018.07.015 (2018).","journal-title":"Osteoarthr. Cartil."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77345-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77345-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77345-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T23:52:39Z","timestamp":1670370759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77345-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["77345"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-77345-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,1]]},"assertion":[{"value":"2 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20915"}}